← FDA DRUG APPROVALS
FDA ANDA · ANDA209635
QUETIAPINE EXTENDED RELEASE
quetiapine
Sponsor: SCIEGEN PHARMS
APPLICATION
ANDA209635
TYPE
ANDA
ORIGINAL APPROVAL
2017-11-29
LATEST ACTION
2023-05-11
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription
Products
QUETIAPINE FUMARATEPrescription
QUETIAPINE FUMARATE EQ 200MG BASE · TABLET, EXTENDED RELEASE · ORAL
QUETIAPINE FUMARATEPrescription
QUETIAPINE FUMARATE EQ 50MG BASE · TABLET, EXTENDED RELEASE · ORAL
QUETIAPINE FUMARATEPrescription
QUETIAPINE FUMARATE EQ 300MG BASE · TABLET, EXTENDED RELEASE · ORAL
QUETIAPINE FUMARATEPrescription
QUETIAPINE FUMARATE EQ 150MG BASE · TABLET, EXTENDED RELEASE · ORAL
QUETIAPINE FUMARATEPrescription
QUETIAPINE FUMARATE EQ 400MG BASE · TABLET, EXTENDED RELEASE · ORAL
Approval history
2023-05-11Labeling · Supplement 13 · standardAP
2020-10-30Labeling · Supplement 8 · standardAP
2020-10-30Labeling · Supplement 10 · standardAP
2020-10-30Labeling · Supplement 9 · standardAP
2020-01-27Labeling · Supplement 3 · standardAP
2020-01-27Labeling · Supplement 6 · standardAP
2017-11-29UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.